Bayer's Courtroom Reckoning in Missouri Tests a Rebuilding Story

Bayer shares slid 2.4% to EUR 46.62 as a fresh Missouri glyphosate trial began, testing whether its Roundup legal exposure is contained.

A fresh glyphosate trial in Missouri has reopened one of the most closely watched legal fronts in European pharma, and Bayer shareholders felt the chill immediately. The Leverkusen-based agriculture and pharmaceutical group slid 2.4% to EUR 46.62 as the proceedings got underway, with the broader market offering no cover: stubborn eurozone inflation, rising oil prices and climbing bond yields had already dragged the DAX firmly into the red, and Bayer's own decline reached 2.7% to EUR 47.75 at one point during Wednesday's session.

At the center of the case are three plaintiffs who argue that Monsanto, Bayer's US subsidiary, failed to test the glyphosate-based herbicide Roundup adequately before bringing it to market. That line of attack differs from the warning-label claims that have dominated previous litigation, which is precisely why observers are treating the Missouri trial as a bellwether for how much legal exposure remains after the Supreme Court's landmark ruling.

A Settlement Under Review, a Safety Assessment Pending

The legal overhang extends well beyond the new trial. A proposed USD 7.25 billion glyphosate settlement package remains under scrutiny by a Missouri court, while the US Environmental Protection Agency is conducting a fresh safety review of the herbicide, with completion targeted for the end of 2026. Until that picture clears, the market continues to apply a persistent risk discount to the stock.

Each courtroom setback ties up capital and management attention that would otherwise fund strategic investment. How the Missouri proceedings unfold will go a long way toward determining whether existing provisions are sufficient or whether further charges lie ahead.

Pipeline Wins Offer a Counterweight

Set against the legal noise, Bayer's pharmaceutical pipeline has been delivering tangible progress. The FDA recently approved Kerendia for chronic kidney disease in patients with type 1 diabetes — the first new treatment option in that indication in three decades. The company's BlueRock subsidiary also secured orphan drug status on both sides of the Atlantic for its cell therapy candidate Lemiretprocel, aimed at primary photoreceptor diseases such as retinitis pigmentosa. The FDA granted the designation for retinitis pigmentosa and cone-rod dystrophy, while the EMA followed suit for certain inherited retinal conditions.

Earlier in the week, the FDA handed priority review status to Lynkuet (elinzanetant) for moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer — a step that shortens the path to a potential launch. Such designations carry expanded market and development privileges, and they underscore the group's capacity to innovate even while its legal docket weighs on sentiment.

A Quarter That Looks Softer Than It Sounds

The operational picture is more nuanced than the pipeline headlines suggest. Deutsche Bank Research weighed in on Tuesday, with analyst Virginie Boucher-Ferte projecting 1.3% year-on-year operating sales growth for the upcoming third quarter — but a 10% decline in operating profit. The culprit is a favorable one-off in the agricultural business that flattered the prior-year quarter, making the comparison look harsher than the underlying trend.

Whether the core earnings base is sturdy enough to absorb ongoing legal uncertainty is the real test for the valuation. Investors must judge if structural profitability in Crop Science, which has been shaped by swings in global commodity and crop-protection markets, can generate enough of a buffer for potential settlements. The group also moved to shore up financial flexibility on 23 September with a hybrid bond placement, and Deutsche Bank reaffirmed its buy rating and EUR 60 price target.

Institutional Money Steps Back

Not everyone shares that optimism. A voting rights notification on Tuesday showed asset manager Amundi trimming its Bayer stake, with its holding falling from 3.04% to 2.90% after crossing a threshold on 23 September. Further withdrawals by institutional capital could cap the share price even if business data hold up. The macroeconomic backdrop for cyclical agrochemical products remains fragile as well: higher interest rates make refinancing more expensive, and volatile end markets squeeze margins.

On the bearish side, the worry is that Missouri hands plaintiffs fresh momentum. If the argument that Roundup was inadequately tested resonates with juries, efforts to contain the wave of claims could falter, and the viability of remaining lawsuits would stay uncomfortably high despite the Supreme Court ruling. That outcome would not only jeopardize the USD 7.25 billion settlement but also narrow room for future deals. The balance sheet would then require additional provisions, keeping leverage elevated and weighing on future dividends. A negative result from the EPA safety review by the end of 2026 would add further pressure on the US Roundup business.

Chart Levels and the November Print

Technically, the picture remains constructive as long as the stock stays clear of key trend lines. At EUR 47.75, the shares sit comfortably above their 200-day moving average of EUR 43.00. If buyers defend that level, the medium-term uptrend stays intact; a significant break below it would hand the bears the upper hand.

The next hard catalyst is already circled: on 3 November 2026, Bayer's management board will present full third-quarter results. Until then, market watchers will parse every twist in the Missouri courtroom. Only when it becomes clear that the remaining claims are manageable will the stock get the room it needs for a sustained breakout.